ICPT - INTERCEPT PHARMACEUTICALS, INC.
IEX Last Trade
10.65
0.260 2.441%
Share volume: 789,330
Last Updated: Tue 08 Aug 2023 09:59:59 PM CEST
Pharmaceutical Preparation Manufacturing :
2.72%
PREVIOUS CLOSE
CHG
CHG%
$10.39
0.26
2.50%
Fundamental analysis
27%
Profitability
33%
Dept financing
46%
Liquidity
30%
Performance
16%
Performance
5 Days
-3.80%
1 Month
-8.05%
3 Months
-35.71%
6 Months
-52.14%
1 Year
-36.72%
2 Year
-37.48%
Key data
Stock price
$10.65
DAY RANGE
N/A - N/A
52 WEEK RANGE
$8.82 - $21.86
52 WEEK CHANGE
-$0.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Jerome B. Durso
Region: US
Website: interceptpharma.com
Employees: 440
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing
Region: US
Website: interceptpharma.com
Employees: 440
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. Intercept also has a license agreement with Aralez Pharmaceuticals Canada to develop and commercialize bezafibrate.
Recent news